

REDX PHARMA PLC
("Redx" or "the Company")

Change of Auditor

Alderley Park, 4 June 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces the appointment of Ernst & Young LLP ('EY') as the Company's auditor for the financial year ending 30 September 2021 following the conclusion of a competitive tender process led by the Company's Audit Committee. The appointment of EY for the subsequent financial year will be subject to approval by the Company's shareholders at the next Annual General Meeting to be held in 2022.

RSM UK Audit LLP ("RSM"), have consequently resigned as auditors. RSM has confirmed to the Company that there are no circumstances connected with its resignation which it considers should be brought to the attention of the members or creditors of the Company.

The Company would like to thank RSM for their support over the last six years.

For further information, please contact:

Redx Pharma Plc **T: +44 1625 469 918**
Peter Presland, Interim Chairman
Lisa Anson, Chief Executive
Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser) **T: +44 203 368 3550**
Matt Davis/Adam Dawes

WG Partners LLP (Joint Broker) **T: +44 20 3705 9330**
Claes Spång/ David Wilson

Panmure Gordon (UK) Limited (Joint Broker) **T: +44 20 7886 2500**
Rupert Dearden/Freddy Crossley/Emma Earl

FTI Consulting **T: +44 20 3727 1000**
Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies and Redx intends to report the Phase 1 clinical study results at a scientific meeting, as well as initiate multiple Phase 2 studies in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, and has previously completed preclinical asset transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and Jazz Pharmaceuticals.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPDKNBQPBKDQAK